Literature DB >> 9468571

Modulation of methotrexate resistance by genistein in murine leukemia L1210 cells.

Y Xuan1, M P Hacker, T R Tritton, A Bhushan.   

Abstract

We have previously shown that methotrexate (MTX) transport is impaired in murine L1210 cells selected for cisplatin (DDP) resistance (L1210/DDP) and that the decreased MTX uptake may be due to an altered 66 kDa membrane protein. We have further hypothesized that tyrosine phosphorylation is necessary for the function of this protein. To determine the importance of tyrosine phosphorylation we studied the effect of genistein, a tyrosine kinase inhibitor, on methotrexate sensitivity, uptake and tyrosine phosphorylation of the 66 kDa protein in L1210/0 cells. After 5 h of treatment with 50 microM genistein, methotrexate uptake was decreased by nearly 50% and the cells were protected from methotrexate cytotoxicity. Immunoblotting of whole cell lysates with a phosphotyrosine monoclonal antibody demonstrated that genistein treatment decreased phosphorylation of the 66 kDa membrane protein. We concluded that phosphorylation of a 66 kDa protein may be critical for methotrexate transport and that genistein protects L1210/0 cells from methotrexate toxicity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9468571

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  2 in total

Review 1.  Tyrosine kinase inhibitors in preclinical development.

Authors:  M L Levitt; P P Koty
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

2.  Identification and characterization of a 66-68-kDa protein as a methotrexate-binding protein in murine leukemia L1210 cells.

Authors:  Tuoen Liu; Allison Dean; Saint Ashwini; Peter P Sheridan; Alok Bhushan; James C K Lai; Shousong Cao; Christopher K Daniels
Journal:  Cell Stress Chaperones       Date:  2012-10-23       Impact factor: 3.667

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.